CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 231 enrolled
Drug / intervention
Xyrem +3 moredrug
Likely dose
Sodium oxybate (Xyrem) 9 g/day oral solution (titrated from 6 g/day); Modafinil 200-600 mg/day oralAI-extracted
Key inclusion· 4
  • Diagnosed with narcolepsy per International Classification of Sleep Disorders criteria
  • Currently on stable modafinil dose (200-600 mg/day) for ≥3 months, stable for ≥1 month before entry
  • Age ≥18 years
  • Able and willing to complete entire trial protocol including transportation arrangements
Key exclusion· 9
  • Sleep apnea (Apnea Index >10/hour or AHI >15/hour)
  • Other primary causes of excessive daytime sleepiness (e.g., severe periodic leg movement syndrome, sleep deprivation)
  • Current use of hypnotics, tranquilizers, sedating antihistamines, benzodiazepines, or clonidine
  • Any anticonvulsant use—ineligible even with planned washout

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00066170
NCT00066170Phase 3Completed

Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy

Jazz Pharmaceuticals·interventional·Posted Aug 6, 2003·Updated Dec 29, 2011

In Brief

A Phase 3 clinical trial evaluating Xyrem, Xyrem Placebo, and 2 other interventions for Narcolepsy. Completed, enrolled 231 participants across 40 sites in 4 countries.

Detailed Summary

This study will be conducted as a randomized, double blind, double-dummy, placebo-controlled, parallel-group trial in patients diagnosed with narcolepsy. Volunteers for this trial will be required to make 5 visits over up to 14 weeks to a participating expert physician practitioner for various sleep and narcolepsy evaluations and diaries will also be collected. Participants will take assigned medications during the course of the trial. Subjects will have a 25% probability of receiving placebo for both drugs (modafinil and Xyrem). All subject volunteers must meet criteria for narcolepsy and have evidence of daytime sleepiness. Patients will not incur any personal medical expenses due to participation in this trial. The sponsor is covering all visit costs not covered by insurance and there are some funds for patient expenses such as travel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNarcolepsy
CountriesFrance, Germany, Switzerland, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 6, 2003
Enrollment StartApr 1, 2003
Primary CompletionJul 1, 2004
Study CompletionNov 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 22.9 years ago

Interventions

Xyremdrug

Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.

Xyrem Placebodrug

Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.

Modafinil at established dosedrug

Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.

Modafinil (Placebo)drug

Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.